Payment overview · 2025
General Payments
$444.25
26 reported records · 16 companies
Healthcare provider profile · identity verified
Billie Jo Rapol
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BOONE, NC · NPI 1518432897
Verified facts
What the public records show
CMS Open Payments records show Billie Jo Rapol received $444.25 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.16 | 23.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.81 | 11.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.07 | 10.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.45 | 7.3% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $22.16 | 5.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.50 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.70 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.28 | 4.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.50 | 3.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.50 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.05 | 3.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.25 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.14 | 3.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.06 | 3.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.00 | 3.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.62 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.25 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $61.18 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.07 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.98 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 228 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 214 | 69 |
| Alprazolam | Alprazolam | 197 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 63 |
| Omeprazole | Omeprazole | 189 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 56 |
| Losartan Potassium | Losartan Potassium | 164 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 47 |
| Tramadol Hcl | Tramadol Hcl | 146 | 56 |
| Methylprednisolone | Methylprednisolone | 145 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 25 |
| Gabapentin | Gabapentin | 100 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 62 |
| Synthroid | Levothyroxine Sodium | 97 | 20 |
| Jardiance | Empagliflozin | 88 | 21 |
| Ozempic | Semaglutide | 88 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 28 |
| Potassium Chloride | Potassium Chloride | 85 | 24 |
| Lisinopril | Lisinopril | 83 | 29 |
| Metformin Hcl | Metformin Hcl | 82 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 63 |
| Allopurinol | Allopurinol | 70 | 18 |
| Furosemide | Furosemide | 70 | 30 |
| Valsartan | Valsartan | 67 | 15 |
| Trazodone Hcl | Trazodone Hcl | 63 | 24 |
| Simvastatin | Simvastatin | 61 | 21 |
| Alendronate Sodium | Alendronate Sodium | 59 | 16 |
| Eliquis | Apixaban | 59 | 15 |
| Buspirone Hcl | Buspirone Hcl | 57 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 29 |
| Montelukast Sodium | Montelukast Sodium | 44 | 13 |
| Mounjaro | Tirzepatide | 44 | 17 |
| Pregabalin | Pregabalin | 44 | 18 |
| Ondansetron Odt | Ondansetron | 42 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 17 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 31 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Prednisone | Prednisone | 40 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 11 |
| Carvedilol | Carvedilol | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 22 |
| Finasteride | Finasteride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 12 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.25 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Flexitouch Plus, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, Nimbl, OTEZLA, Ozempic, QULIPTA, REPATHA, Symbravo, UBRELVY, UNITHROID, ZENPEP, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error